Company Filing History:
Years Active: 2021-2024
Title: Innovations of Huiying Han in Cancer Therapeutics
Introduction
Huiying Han is an accomplished inventor based in Chicago, IL, known for her significant contributions to the field of cancer therapeutics. With a total of four patents to her name, she has focused her research on developing innovative compounds that target critical proteins involved in cancer progression.
Latest Patents
Among her latest patents, one notable invention is the development of substituted heterocycles as c-MYC targeting agents. This patent discloses various substituted heterocycle compounds, including substituted pyrazoles, pyrimidines, and triazoles. These compounds have shown potential in inhibiting c-MYC, making them valuable for therapeutic applications in treating cancer and cell proliferative disorders. Another significant patent involves proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of the c-MYC protein. This invention describes PROTACs that include a targeting moiety binding to c-MYC, linked to another moiety that binds to an E3 ubiquitin ligase, thereby facilitating the degradation of the c-MYC protein.
Career Highlights
Huiying Han has made remarkable strides in her career, particularly through her work at Northwestern University. Her research has not only advanced the understanding of cancer biology but has also paved the way for new therapeutic strategies.
Collaborations
Huiying has collaborated with esteemed colleagues, including Gary E Schiltz and Sarki A Abdulkadir, to further her research endeavors. These collaborations have enriched her work and contributed to the development of innovative solutions in cancer treatment.
Conclusion
Huiying Han's innovative work in developing targeted cancer therapies showcases her dedication to advancing medical science. Her patents reflect a commitment to finding effective treatments for cancer, highlighting her role as a leading inventor in this critical field.